Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

38 results about "Triaziquone" patented technology

Triaziquone is a drug used in chemotherapy. It is an alkylating agent. It can react with DNA to form intrastrand crosslinks.

Composition comprising a novel UV filter combination

PCT designated stageWO2025257312A1Cosmetic preparationsToilet preparationsBenzoic acidEthylhexyl triazone
The invention relates to a composition comprising (i) more than 0.5 wt.% of a compound according to formula (Ia) or a salt, hydrate, stereoisomer, tautomer or N-oxide thereof, based on the total weight of the composition, and (ii) 4,4ʼ,4ʼʼ-(1,3,5-triazin-2,4,6-triyltriimino)tris-benzoic acid tris(2-ethylhexyl)ester (INCI ethylhexyl triazone).
Owner:BASF SE

Thienopyrrolotriazinone compounds and their uses

The present invention belongs to the field of chemical medicine and provides a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The present invention provides a class of compounds with a skeleton of thiophenopyrrolotriazinone, which can be used to prepare NLRP3 inflammasome inhibitors and provides a new option for preparing drugs for treating diseases caused by abnormal activation of NLRP3 inflammasome.
Owner:CHENGDU ZENITAR BIOMEDICAL TECH CO LTD

Refining method of diethylhexyl butyrylamide triazinone

The invention provides a refining method of diethylhexyl butyrylamide triazinone, and belongs to the technical field of cosmetics. Comprising the following steps: carrying out reactive crystallization on an impurity-containing compound shown in formula III in a first solution, and filtering to separate out crystal crystals to obtain a compound shown in formula IV; wherein the first solution is formed by dissolving hydrogen chloride in a second solvent; and reacting the compound of formula IV with an alkaline compound solution to obtain a refined compound of formula III. According to the method, impurities are removed in a mode of salifying and crystallizing hydrogen chloride and diethyl hexyl butyrylamide triazinone which are dissolved in a second solvent; and neutralizing hydrogen chloride in the formed salt to obtain the high-purity diethylhexyl butyrylamide triazinone, so that the purity of the diethylhexyl butyrylamide triazinone is improved.
Owner:SICHUAN WERLCHEM FINE CHEM CO LTD

Sunscreen composition as well as preparation method and application thereof

The invention relates to the technical field of skin care products, in particular to a sunscreen composition as well as a preparation method and application thereof. The sunscreen composition is prepared from a carrier, a sunscreen agent component and a sunscreen synergistic component, wherein the sunscreen agent component and the sunscreen synergistic component are entrapped by the carrier; the sunscreen agent component is prepared from avobenzone, diethylhexyl butyrylamide triazinone and bis-ethylhexyloxyphenol methoxyphenyl triazine; the sunscreen synergistic component is prepared from carrot seed oil and herba siegesbeckiae extract. According to the sunscreen composition, AVB, DHBT and BEMT are combined with sunscreen synergistic components including carrot seed oil and herba siegesbeckiae extract, and the sunscreen composition with remarkably excellent sunscreen capacity and safety is obtained through the synergistic effect of all the components and has important value in the related production field of skin care products.
Owner:HUBEI MEIFENG TECHNOLOGY DEVELOPMENT CO LTD +6

Novel pyrrolo [1, 2-d] [1, 2, 4] triazinone derivatives as MGLU7 receptor negative allosteric modulators

The present application relates to compounds of formula (I) wherein P, Q, A, B, m, n, R1, R2 and R3 are as defined in formula (I); the compounds are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and are useful in the treatment or prevention of nervous, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which mGlu7 metabotropic receptor subtype is involved. The present application also relates to pharmaceutical compositions comprising such compounds; methods of making such compounds and such compositions; and the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases, in which mGlu7 is involved. # imgabs0 #
Owner:NEUROSTERIX PHARMA SÀRL

Preparation method of 4-amino-6-tert-butyl-3-sulfydryl-1, 2, 4-triazine-5 (4H)-ketone

PendingCN121378163AOrganic chemistryThio-Ketone
The invention discloses a preparation method of 4-amino-6-tert-butyl-3-sulfydryl-1, 2, 4-triazine-5 (4H)-ketone and a preparation method of the 4-amino-6-tert-butyl-3-sulfydryl-1, 2, 4-triazine-5 (4H) The preparation method comprises the following steps: dissolving 3, 3-dimethyl-2-oxobutyric acid methyl ester in a solvent, adjusting the pH value to be acidic, then adding thiocarbazide and DMAP (Dimethylamino Phosphate), carrying out a heating reaction, and after the reaction is finished, carrying out filtering, solid separation, washing and vacuum drying in sequence to prepare 4-amino-6-tert-butyl-3-sulfydryl-1, 2, 4-triazine-5 (4H)-ketone. The extraction solvents used in all the steps are the same, the reaction solvent is mainly water and can be removed through anhydrous sodium sulfate, and when the reaction solvent is alcohol, the alcohol can be removed through rotary evaporation. Therefore, the discharge amount of three wastes in the reaction is small, the potential safety hazard is small, and the product yield and purity are high; raw material cost is low, and industrial production is facilitated.
Owner:QINGDAO UNIV OF SCI & TECH

Method for preparing diethylhexyl butyramido triazinone by one-pot method

The invention discloses a method for preparing diethylhexyl butyrylamide triazinone, which comprises the following steps: S1, in the presence of an organic acid-binding agent, carrying out substitution reaction on N-tert-butyl-4-aminobenzamide and cyanuric chloride in a non-polar solvent at-10 DEG C to 60 DEG C for 1-6 hours to obtain an untreated substitution reaction mixture; and S2, adding isooctyl p-aminobenzoate into the substitution reaction mixture obtained in the step S1, and carrying out a reaction at 15-120 DEG C for 3-15 h so as to finally prepare the diethylhexyl butyramido triazinone. According to the method, the organic acid-binding agent is used, so that the substitution reaction is more stable, byproducts are fewer, and the product purity is higher. Meanwhile, due to the adoption of the organic acid-binding agent, a non-polar solvent can be conveniently used in the step of substitution reaction, so that a substitution reaction mixture can be directly subjected to next-step reaction with isooctyl p-aminobenzoate without treatment, and the one-pot preparation of the diethylhexyl butyrylamide triazinone is realized.
Owner:HUBEI HUIDA HIGH TECH CO LTD +1

Preparation method of pyrazolo [1, 3-a] [1, 2, 4] triazine-6-ketone compound

The invention discloses a chiral pyrazolo [1, 3-a] [1, 2, 4] triazine-6-ketone compound and a preparation method of the chiral pyrazolo [1, 3-a] [1, 2, 4] triazine-6-ketone compound. According to the method, under the action of a copper catalyst generated in situ by a metal copper precursor and a chiral pyridine bisoxazoline ligand in a reaction medium, an ethynyl methylene cyclocarbamate compound and an azomethine compound are subjected to a [3 + 3] cyclization reaction, and the chiral pyrazolo [1, 3-a] [1, 2, 4] triazine-6-ketone compound is obtained with high yield and high enantioselectivity. The method has the characteristics of cheap catalyst precursor, easily available ligand, high activity, high selectivity, mild reaction conditions, simplicity and convenience in operation and the like.
Owner:DALIAN INSTITUTE OF CHEMICAL PHYSICS CHINESE ACADEMY OF SCIENCES

2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R1 is C1-C3alkyl optionally substituted with F, C3-C6cycloalkyl, C1-C3alkoxy; X represents a bond or C1-C3alkylene optionally substituted with OH, ONO, ONO2; R2 is H, OH, ONO, ONO2, C(O)OH, C(O)OC1-C3alkyl, CHO, CN, C1-C3alkoxy, OC(O)H, OC(O)—C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl, CR8═N—OR9, CR8═N—NR10R11, CR8═NR12 or CR8═N—ONO2; R3 is C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, C1-C3alkoxy, C3-C6cycloalkyl; C3-C6cycloalkyl, C2-C6alkenyl, C2-C6alkynyl; R4 is C1-C6alkyl optionally substituted with C3-C6cycloalkyl, C1-C6alkoxy, F, ONO, ONO2; C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl; R5 is H, SO2N—R13R14, NHSO2NR13R14; R6 is H or C1-C3alkyl; R7 is H, C1-C3alkyl, C1-C3alkoxy, C1-C3alkyl substituted with phenyl, benzyl or a heterocyclic ring, wherein said phenyl, benzyl or said heterocyclic ring are independently optionally substituted by C1-C3alkyl, F; R8 is H, CH3 or C2H5; R9: H, C1-C3alkyl optionally substituted with OH, ONO, ONO2, CN, COOH, COOC1-C3alkyl, C1-C3alkoxy, OC(O)H, OC(O)—C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl; R10 and R11 are each independently H, C1-C3alkyl optionally substituted with OH, ONO, ONO2, CN, COOH, COOC1-C3, C1-C3alkoxy, OC(O)H, OC(O)—C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl; i or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrolidine, piperidine, morpholine, piperazine and homopiperazine, wherein said heterocyclic ring is optionally substituted with C1-C3 alkyl; R12 is C1-C3 alkyl optionally substituted with OH, ONO, ONO2, CN, COOH, COOC1-C3alkyl, C1-C3alkoxy, OC(O)H, OC(O)—C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl; R13 and R14 are each independently H or C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, COOH, C1-C3alkoxy, C3-C6Cycloalkyl; or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrolidine, piperidine, morpholine, piperazine, homopiperazine, 2,5-diazabicyclo[2,2,1]heptane and 3,7-diazabicyclo[3,3,0]octane, wherein said heterocyclic ring is optionally substituted with R15; R15 is C1-C6alkyl optionally substituted with halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR16, NR17R18, C═NR19, or with a tetrazole group which is optionally substituted with C1-C3alkyl; or a heteroaryl ring which is optionally substituted with F, wherein the at least one heteroatom of said heteroaryl ring is nitrogen; R16 is H, or C1-C4alkyl optionally substituted with F, OH, ONO, ONO2, NR17R18, or with a heteroaryl ring, wherein the at least one heteroatom of said heteroaryl ring is nitrogen, and wherein preferably said heteroaryl ring is selected from pyrrolidine, piperidine, piperazine, morpholine, pyrrole, and imidazole, wherein nitrogen atom is directly bound to C1-C4 alkyl; R17 and R18 are each independently H or C1-C4alkyl optionally substituted with ONO, ONO2; R19 is C1-C4alkyl optionally substituted with F, ONO, ONO2; C3-C6Cycloalkyl; and their use in methods of treating or preventing a disease alleviated by inhibition of PDE-5 in a human or in a non-human mammal.
Owner:TOPADUR PHARMA AG

Triazinone hydrolysis device

The utility model discloses a triazinone hydrolysis device which comprises a reaction kettle, the upper surface of the reaction kettle is fixedly connected with a motor, the output end of the motor is fixedly connected with a rotating column, the outer surface of the rotating column is fixedly connected with four inclined scrapers, the middle of the outer surface of the reaction kettle is fixedly connected with an oil collecting block, and the oil collecting block is fixedly connected with an oil outlet of the oil collecting block. An oil removing groove is formed in the oil collecting block, the oil removing groove is communicated with the interior of the reaction kettle, in-groove baffles are fixedly connected to the lower surfaces of the four inclined scraping plates, the in-groove baffles are located in the oil removing groove, and four oil removing pipes are fixedly connected to the lower surface of the oil collecting block; oil storage pipes are fixedly connected to the lower surfaces of the four oil removing pipes, oil outlet pipes are fixedly connected to the lower surfaces of the oil storage pipes, and mechanical valves are fixedly connected to the interiors of the oil outlet pipes. The inclined scraping plate rotates along with the rotation of the rotating column, and the oil dirt moves in the specific direction along the track of the scraping plate by utilizing the inclination angle and the rotating force, so that the oil dirt collecting efficiency is improved.
Owner:NINGXIA CAIYUAN TECH CO LTD

1,2,3-benzotriazine-4(3h)-one selenide and preparation method and application thereof

The application provides a 1,2,3-benzotriazine-4(3H)-ketone selenide and a preparation method and application thereof, and belongs to the field of organic synthesis. The 1,2,3-benzotriazine-4(3H)-ketone selenide has anti-schistosome activity. The preparation method has the advantages of mild conditions, easy control, high reaction efficiency, economical steps, cheap and easily available raw materials, no use of oxidants, good functional group tolerance and the like, and the prepared 1,2,3-benzotriazine-4(3H)-ketone selenide has high purity, the purity is 98.5-99.9%, and has great market promotion value. Compared with a multi-step synthesis reaction, the target product can be obtained through one-step reaction, the reaction yield reaches 90%, and the reaction has the advantages of high reaction efficiency and economical steps.
Owner:GANNAN NORMAL UNIV

NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS

PendingUS20260184715A1DiseaseNervous system
The present application relates to compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R2 and R3 are defined as in Formula (I) which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The application is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.
Owner:ADDEX PHARMACEUTICALS SA

Novel pyrrolo[1,2-d][1,2,4]triazinone derivatives as negative allosteric modulators of the MGLU7 receptor

TIFF2025538048000094.tif34115 The present invention relates to novel compounds of formula (I), wherein P, Q, A, B, m, n, R 1 , R 2 and R 3 are defined as in Formula (I); which are negative allosteric modulators of metabotropic glutamate receptor subtype 7 (mGlu7) and are useful for treating or preventing neurological, otic, and psychiatric disorders associated with glutamate dysfunction, and disorders involving the mGlu7 subtype of metabotropic receptor. The present invention is also directed to pharmaceutical compositions comprising such compounds, processes for preparing such compounds and such compositions, and the use of such compounds for the prevention or treatment of neurological, otic, and psychiatric disorders involving mGlu7.
Owner:NEUROSTERIX PHARMA SÀRL

Fused triazinone derivatives and methods of using the same

The present disclosure relates to compounds of Formula (I) or (II) or subformulas thereof: (I) and do their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds of the present disclosure may act as small molecule splicing modulator that modulate splicing of mRNA, such as pre-mRNA, encoded genes, and methods of use of the compounds for modulating splicing and treating related diseases and conditions. The compounds disclosed herein may possess activity toward various genetic pathways and are accordingly useful in methods of treatment of the human or animal body.
Owner:RGENTA THERAPEUTICS INC

Method for determining multiple sun-screening agents in serum

The embodiment of the invention discloses a method for determining multiple sun-screening agents in serum, the method can be used for determining the sun-screening agents, and the method comprises the following steps: obtaining a to-be-detected sample according to to-be-detected serum; performing chromatography and mass spectrometry on the to-be-detected sample under a predetermined detection condition to obtain peak area data corresponding to the multiple sun-screening agents; acquiring the concentration of each sun-screening agent in the serum to be detected according to the linear equation and the peak area data of each sun-screening agent; the multiple sun-screening agents comprise at least one of cresol trozole trisiloxane and ethyl hexyl triazinone.
Owner:SHENZHEN GANGZHONGYAN BIOTECHNOLOGY CO LTD

Formulations containing triazinones and iron

UndeterminedES3084030T3BiotechnologyIron deficient
The present invention relates to formulations comprising triazinones, such in particular toltrazuril and diclazuril, and complex polynuclear iron polysaccharide compounds together with the surfactant dioctyl sulfosuccinate to combat coccidiosis infections and iron deficiency states, especially in suckling piglets.
Owner:ELANCO ANIMAL HEALTH GMBH

Synthetic method of pyrrolo [2, 1-f] [1, 2, 4] triazine-4 (3H)-ketone

The embodiment of the invention discloses a synthetic method of pyrrolo [2, 1-f] [1, 2, 4] triazine-4 (3H)-ketone. The synthesis method comprises the following steps: taking 2, 5-dimethoxytetrahydrofuran and tert-butyloxycarboryl hydrazine as initial raw materials, and sequentially carrying out Clawson-Kass pyrrole synthesis reaction, formylation reaction, deprotection group reaction and cyclization reaction to prepare pyrrolo [2, 1-f] [1, 2, 4] triazine-4 (3H)-ketone. Reagents and solvents used in the method are cheap and easy to obtain, reaction conditions of key steps are mild, a reliable technical scheme is provided for industrial production, and the method is a synthesis method with large-scale preparation value and has good application value.
Owner:GUIZHOU PAOZHIYUAN BIOTECHNOLOGY CO LTD

Preparation device and process of triazinone

The invention discloses a triazinone preparation device and process, and relates to the technical field of triazinone preparation, the triazinone preparation device comprises a base, one side of the base is provided with a support, and the base is provided with a hydrolysis kettle, an oxidation kettle and a cyclization kettle; electromagnetic control valves are respectively arranged on the outer sides of the hydrolysis kettle and the cyclization kettle; a butt joint transmission mechanism is arranged on the outer side of the oxidation kettle and is used for transmitting materials; materials are subjected to a hydrolysis reaction in the hydrolysis kettle, are conveyed into the oxidation kettle through the butt joint conveying mechanism for an oxidation reaction, and then are conveyed into the cyclization kettle for a cyclization reaction; an executing mechanism is arranged on the support and comprises an installation frame installed on the support in a sliding mode, a deflection plate is rotationally arranged on the installation frame, and a scraping piece, a checking piece and a removing piece are further sequentially arranged on the installation frame. A stirring shaft is telescopically arranged on the deflection plate and is used for stirring treatment; according to the invention, preparation of triazinone can be efficiently realized, and material transmission is convenient, so that subsequent maintenance operation is more convenient.
Owner:NINGXIA CAIYUAN TECH CO LTD

PDE9 inhibitors with imidazotriazine skeleton and imidazopyrazine skeleton for treating peripheral diseases

The present invention relates to PDE9 inhibitors and their use for treating benign prostatic hyperplasia and sickle cell disease. The inhibitory compound can be selected from: 3-(4-fluorophenyl)-6-((3-(pyridin-4-yloxy)azetidin-1-yl)methyl)imidazo[1,5-a]pyrazin-8(7H)-one, 6-[3-(pyridin-3-yloxy)azetidin-1-ylmethyl]-3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one, 6-(4-methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl)-3-(tetrahydro- imidazo[1,5-a]pyrazin-8-one, (3S,4S)-6-(4-methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl)-3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one, and (3R,4R)-6-(4-methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl)-3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one.
Owner:H LUNDBECK AS

PYRAZOLO[5,1- f][1,2,4]TRIAZIN-4-ONES AS INHIBITORS OF NOX4

The present disclosure provides pyrazolo[5,1-f][1,2,4]triazin-4-ones that are inhibitors of NOX4, and are therefore useful for the treatment of diseases treatable by inhibition of NOX4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
Owner:BOEHRINGER INGELHEIM INT GMBH

Photoprotective system consisting of 4 sunscreens

The present invention relates to a cosmetic or pharmaceutical composition comprising at least one cosmetically or pharmaceutically acceptable excipient and a photoprotective system consisting of: (a) 5,6,5′,6′-tetraphenyl-3,3′-(1,4-phenylene)-bis[1,2,4]triazine, (b) 2,4-bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, (c) hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate, and (d) a solar filter selected from the group comprised of ethylhexyl triazone, diethylhexyl butamido triazone and 2-ethylhexyl salicylate, wherein the photoprotective system represents between 4% and 20% by weight of the composition relative to the total weight of the composition.
Owner:PIERRE FABRE DERMO COSMETIQUE SA

Triazinone derivatives as NLRP3 inhibitors

The present invention relates to a novel compound having the formula: 6-[[(3R)-1-ethyl-3-piperidinyl] amino]-3-(4-hydroxyindan-5-yl)-4-methyl-1, 2, 4-triazine-5-one or 6-[[(3R)-1-ethyl-3-piperidinyl] amino]-3-(2-hydroxy-3-bicyclo [4.2. 0] oct-1, 3, 5-trialkenyl)-4-methyl-1, 2, 4-triazine-5-one, and a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition comprising the same. Comprising the compound; and methods of using the compounds. # imgabs0 #
Owner:F HOFFMANN LA ROCHE & CO AG